Empagliflozin: a Wonder Drug for the Treatment of SIAD?

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Oct 22

PMID 39435353

Authors

Ploutarchos Tzoulis

Affiliations

Soon will be listed here.

Citing Articles

Hypertension approaches and recent SGLT2i studies.

Bloomgarden Z J Diabetes. 2024; 16(11):e70034.

PMID: 39582313 PMC: 11586533. DOI: 10.1111/1753-0407.70034.

References

Kani R, Watanabe A, Miyamoto Y, Ejiri K, Iwagami M, Takagi H . Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2024; 13(3):e031805. PMC: 11056162. DOI: 10.1161/JAHA.123.031805. View

Charaya K, Shchekochikhin D, Agadzhanyan A, Vashkevich M, Chashkina M, Kulikov V . Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure. Cardiorenal Med. 2023; 13(1):101-108. DOI: 10.1159/000529614. View

Haring H, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle H . Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11):3396-404. PMC: 3816918. DOI: 10.2337/dc12-2673. View

Braunwald E . Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022; 386(21):2024-2034. DOI: 10.1056/NEJMra2115011. View

Anker S, Butler J, Filippatos G, Ferreira J, Bocchi E, Bohm M . Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385(16):1451-1461. DOI: 10.1056/NEJMoa2107038. View

Nicco C, Wittner M, Distefano A, Jounier S, Bankir L, Bouby N . Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension. 2001; 38(5):1143-9. DOI: 10.1161/hy1001.092641. View

Sarafidis P, Ferro C, Morales E, Ortiz A, Malyszko J, Hojs R . SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019; 34(2):208-230. DOI: 10.1093/ndt/gfy407. View

Kohler S, Zeller C, Iliev H, Kaspers S . Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Adv Ther. 2017; 34(7):1707-1726. PMC: 5504200. DOI: 10.1007/s12325-017-0573-0. View

Handelsman Y, Henry R, Bloomgarden Z, Dagogo-Jack S, DeFronzo R, Einhorn D . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016; 22(6):753-62. DOI: 10.4158/EP161292.PS. View

10.

Cuesta M, Thompson C . The syndrome of inappropriate antidiuresis (SIAD). Best Pract Res Clin Endocrinol Metab. 2016; 30(2):175-87. DOI: 10.1016/j.beem.2016.02.009. View

11.

Marton A, Kaneko T, Kovalik J, Yasui A, Nishiyama A, Kitada K . Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol. 2020; 17(1):65-77. DOI: 10.1038/s41581-020-00350-x. View

12.

Siafarikas C, Kapelios C, Papatheodoridi M, Vlachogiannakos J, Tentolouris N, Papatheodoridis G . Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use. Liver Int. 2024; 44(4):884-893. DOI: 10.1111/liv.15851. View

13.

Berton A, Parasiliti-Caprino M, Prencipe N, Bioletto F, Lopez C, Bona C . Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study. Front Neurosci. 2023; 17:1098404. PMC: 10067557. DOI: 10.3389/fnins.2023.1098404. View

14.

Monnerat S, Atila C, Refardt J, Christ-Crain M . Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor. J Endocr Soc. 2023; 7(4):bvad011. PMC: 9933898. DOI: 10.1210/jendso/bvad011. View

15.

Yeoh S, Docherty K, Jhund P, Petrie M, Inzucchi S, Kober L . Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. JACC Heart Fail. 2022; 10(5):306-318. DOI: 10.1016/j.jchf.2022.01.019. View

16.

Warren A, Grossmann M, Christ-Crain M, Russell N . Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management. Endocr Rev. 2023; 44(5):819-861. PMC: 10502587. DOI: 10.1210/endrev/bnad010. View

17.

Tzoulis P, Kaltsas G, Baldeweg S, Bouloux P, Grossman A . Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD). Ther Adv Endocrinol Metab. 2023; 14:20420188231173327. PMC: 10192810. DOI: 10.1177/20420188231173327. View

18.

Wanner C, Inzucchi S, Zinman B . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(18):1801-2. DOI: 10.1056/NEJMc1611290. View

19.

Kohler S, Salsali A, Hantel S, Kaspers S, Woerle H, Kim G . Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. Clin Ther. 2016; 38(6):1299-1313. DOI: 10.1016/j.clinthera.2016.03.031. View

20.

Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl U, Woerle H . Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015; 17(10):936-48. PMC: 5034797. DOI: 10.1111/dom.12503. View